Your browser is no longer supported

For the best possible experience using our website we recommend you upgrade to a newer version or another browser.

Your browser appears to have cookies disabled. For the best experience of this website, please enable cookies in your browser

We'll assume we have your consent to use cookies, for example so you won't need to log in each time you visit our site.
Learn more

New combination hayfever treatment launched in UK

  • Comment

A novel nasal spray formulation of fluticasone propionate and azelastine hydrochloride has been launched in the UK for relief of symptoms of moderate to severe seasonal and perennial allergic rhinitis.

The prescription product, branded as Dymista, is licensed for use where monotherapy with either intranasal antihistamine or glucocortocoid is not considered sufficient.

According to trial data presented in March, 17.8% of patients taking Dymista experienced complete or near-to-complete nasal symptom resolution, compared with 9.2% of patients taking fluticasone propionate monotherapy, 8.3% taking azelastine alone and 7.8% of those on a placebo.

The UK license for the treatment has been granted following European Medicines Agency (EMA) approval. It has been available in the US since September 2012.

It is manufactured by Meda Pharmaceuticals.

  • Comment

Have your say

You must sign in to make a comment

Please remember that the submission of any material is governed by our Terms and Conditions and by submitting material you confirm your agreement to these Terms and Conditions. Links may be included in your comments but HTML is not permitted.

Related Jobs